Zim Laboratories discloses inter‑promoter transfer of 80,000 shares to Dr. Anwar Daud

What Zim Laboratories announced

Zim Laboratories Ltd filed a disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on 16 June 2026. The filing records an inter‑promoter transfer of 80,000 equity shares from Mr. Zulfiquar Kamal to Dr. Anwar Daud. The shares represent 0.15 % of the paid‑up equity share capital and voting rights of Zim Laboratories.

The transaction is exempt from an open‑offer requirement under Regulation 10(1)(a)(ii) because it is an intra‑group transfer among promoters. The price ceiling for the acquisition is set at Rs 107.50 per share, as stipulated in the proviso to Regulation 10(1)(a).

Details of the inter‑promoter share transfer

• Acquirer: Dr. Anwar Daud (promoter)\
• Transferor: Mr. Zulfiquar Kamal (promoter)\
• Number of shares transferred: 80,000\
• Percentage of diluted share capital: 0.15 %\
• Price per share: Not to exceed Rs 107.50\
• Regulatory exemption: Regulation 10(1)(a)(ii) of the SEBI SAST Regulations\
• Disclosure filing date: 4 June 2026 (within the timeline prescribed by Regulation 10(5))

The filing confirms that the disclosure was made to both the National Stock Exchange of India Limited (NSE) and BSE Limited, even though Zim Laboratories is currently listed only on BSE under scrip code 541400.

Shareholding impact

The transfer increased Dr. Daud’s stake by 0.15 %, while Mr. Kamal’s stake decreased by the same amount. No new shares were issued; the transaction merely re‑allocated existing equity among promoters, leaving the total share capital unchanged.

Key facts at a glance

Why this matters for investors

The filing satisfies SEBI’s requirement that any acquisition of shares exceeding the 0.1 % threshold be reported to the stock exchanges. Because the transfer is between promoters and does not involve issuance of new shares, there is no dilution of existing shareholders’ equity. The exemption under Regulation 10(1)(a)(ii) also means that the company is not obligated to launch a mandatory open offer, which could have otherwise required additional cash outflow.

From a compliance perspective, Zim Laboratories has adhered to the timeline set out in Regulation 10(5) by filing the disclosure on 4 June 2026, well before the 11 June 2026 deadline. This demonstrates the company’s commitment to regulatory transparency, a factor that can affect the confidence of institutional investors who monitor adherence to SEBI norms.

Conclusion

Zim Laboratories Ltd has recorded an inter‑promoter transfer of 80,000 shares from Mr. Zulfiquar Kamal to Dr. Anwar Daud, amounting to 0.15 % of the company’s equity. The transaction is exempt from an open offer, was priced within the regulatory ceiling of Rs 107.50 per share, and was disclosed within the prescribed timeline. The shareholding pattern now shows a modest increase in Dr. Daud’s stake and a corresponding decrease for Mr. Kamal, with no impact on the total share capital.

The disclosure was filed on 4 June 2026, complying with the timeline required under SEBI Regulation 10(5).